USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: Medarex, Inc.
City: Princeton
State: NJ
Zip+4: 08540
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (908) 479-2464

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $875,908.00 8
SBIR Phase II $684,590.00 1
STTR Phase I $200,000.00 3
STTR Phase II $264,820.00 1

Award List:

IFN-GAMMA BIOASSAYS

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
Ifn- is currently being tested for the treatment of a wide range of diseases including autoimmune and infectious diseases, solid tumors and hematologic malignancies. as with other biological response modifiers, it is difficult to predict the optimal dose for the desired in vivo effect, and two… More

ELIMINATION OF ANTIGEN REACTIVE B CELLS

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
Medarex has exclusive license to several monoclonal antibodies (mabs) reactive to the high affinity fc receptor for igg (fcgri), on human monocytes. this receptor is a critical trigger molecule for adcc by these cells and has been shown to mediate killing of red cell targets and tumor like cells. we… More

BI-SPECIFIC ANTIBODY-DIRECTED KILLING IN HIV THERAPY

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ateeq Ahmad
Award Amount: $50,000.00
Abstract:
Medarex, inc., has exclusive license to several monoclonal antibodies (mabs) reactive to the high-affinity fc receptor for igg (fc ri), which is expressed on human monocytes and, after ifn activation, on human pmns. this receptor is a critical trigger molecule for adcc by these cells. this research… More

REDIRECTING THE IMMUNE SYSTEM FOR ANTICANCER THERAPY

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $53,000.00

DEVELOPMENT OF A NOVEL VACCINE STRATEGY

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $64,000.00

REDIRECTING THE IMMUNE SYSTEM FOR ANTICANCER THERAPY

Award Year / Program / Phase: 1998 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $684,590.00

TWO COMPONENT STRATEGY FOR IMMUNE TARGETING

Award Year / Program / Phase: 1998 / STTR / Phase I
Agency: HHS
Research Institution: Albany Medical College
Principal Investigator: Gosselin
Award Amount: $100,000.00
RI Contact: N/A

N/A

Award Year / Program / Phase: 1999 / STTR / Phase I
Agency: HHS
Research Institution: Dartmouth College
Principal Investigator: Ely
Award Amount: $0.00
RI Contact: N/A

ANTIBODY THERAPY FOR STAPHYLOCOCUUS AUREUS INFECTIONS

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Tibor P. Keler
Award Amount: $100,000.00
Abstract:
Not Available This program will develop high-power visible laser sources based on frequency conversion of 1 micron diode-pumped solid-state lasers. Improvements are needed in efficient and robust nonlinear materials. The technical objectives of our overall research program are to develop… More

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Tibor P. Keler
Award Amount: $100,000.00

An improved targeted vaccine strategy against anthrax

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Tibor P. Keler
Award Amount: $408,908.00
Abstract:
DESCRIPTION (provided by applicant): The long term goal of this proposal is to develop a novel targeted vaccine technology against emerging infectious diseases and pathogens associated with bioterrorism. Previous studies have documented the extremely rapid and potent immune responses elicited by… More